Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors
| Title: | Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors |
|---|---|
| Authors: | Ting Li, Qiaomei He, Jun Yang, Yu Cai, Chongmei Huang, Xiaowei Xu, Huiying Qiu, Jiahua Niu, Kun Zhou, Yin Zhang, Xinxin Xia, Yu Wei, Chang Shen, Xueying Ding, Yin Tong, Liping Wan, Xianmin Song |
| Source: | Cell Transplantation, Vol 31 (2022) |
| Publisher Information: | SAGE Publishing, 2022. |
| Publication Year: | 2022 |
| Collection: | LCC:Medicine |
| Subject Terms: | Medicine |
| More Details: | Maternal and collateral donors were associated with a higher incidence of graft- versus -host disease (GvHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). A more effective regimen for GvHD prophylaxis after haplo-HSCT with maternal/collateral donors needed to be explored. A retrospective study was performed on 62 patients after haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with maternal/collateral donors, which included 35 patients with low-dose antithymocyte globulin (ATG) plus low-dose posttransplant cyclophosphamide-based (low-dose ATG/PTCy-based) and 27 with ATG-based regimens for GvHD prophylaxis. The 180-day cumulative incidences (CIs) of grades II-IV and III-IV acute GvHD (aGvHD) were 17.7% and 6.8% in low-dose ATG/PTCy-based group, which were significantly lower than that in ATG-based group (55.4% and 31.9%) ( P = 0.003 for grade II-IV and P = 0.007 for III-IV aGvHD). In low-dose ATG/PTCy-based group, the 1-year overall survival (OS) and relapse-free survival (RFS) were 80.0%and 80.4%, which were higher than that in ATG-based group with OS of 59.4% and RFS of 62.0%. In multivariate analysis, the low-dose ATG/PTCy-based regimen significantly reduced the risk of grade II-IV (HR = 0.357; P = 0.049) and grade III-IV aGvHD (HR = 0.190; P = 0.046) as an independent risk factor. The results suggested that the low-dose ATG/PTCy-based regimen could effectively prevent the occurrence of aGvHD after haplo-PBSCT with maternal/collateral donors compared with the ATG-based regimen. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1555-3892 09636897 |
| Relation: | https://doaj.org/toc/1555-3892 |
| DOI: | 10.1177/09636897221139103 |
| Access URL: | https://doaj.org/article/ef8218d2c4834898b9ff84f6b5e48bed |
| Accession Number: | edsdoj.f8218d2c4834898b9ff84f6b5e48bed |
| Database: | Directory of Open Access Journals |
| ISSN: | 15553892 09636897 |
|---|---|
| DOI: | 10.1177/09636897221139103 |
| Published in: | Cell Transplantation |
| Language: | English |